Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
Clara Aparicio-Pérez, María Dolores Carmona-Luque, Karim Benabdellah, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21

Showing 21 citing articles:

Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape
You Zhai, Yicong Du, LI Guan-zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 19
CAR-T cell combination therapies in hematologic malignancies
Delian Zhou, Xiaojian Zhu, Yi Xiao
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia
Martijn W. C. Verbeek, Vincent H. J. van der Velden
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4881-4881
Open Access | Times Cited: 5
How I Investigate Measurable Residual Disease in B‐Cell Precursor Acute Lymphoblastic Leukemia After Therapy With Bi‐Specific Monoclonal Antibodies and 19CAR‐T Cells
Maura Rosane Valério Ikoma, Felipe Magalhães Furtado, Elen Oliveira, et al.
International Journal of Laboratory Hematology (2025)
Closed Access
Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy
B. Bogdanovič, Florent Hugonnet, Christopher Montemagno
Cancers (2025) Vol. 17, Iss. 7, pp. 1247-1247
Open Access
Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
Martijn W. C. Verbeek, Michaela Reiterová, Anna Laqua, et al.
HemaSphere (2025) Vol. 9, Iss. 4
Open Access
Expanding the role of CAR T‐cell therapy: From B‐cell hematological malignancies to autoimmune rheumatic diseases
Russka Shumnalieva, Tsvetelina Velikova, Simeon Monov
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 5
Closed Access | Times Cited: 3
Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade
Denis M. Schewe, Fotini Vogiatzi, Ira A. Münnich, et al.
HemaSphere (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 2
Clinicopathologic features of relapsed CD19(−) B‐ALL in CD19‐targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B‐cell marker for CD19(−) B lymphoblasts
Dong Chen, Franklin Fuda, Flavia Rosado, et al.
International Journal of Laboratory Hematology (2024) Vol. 46, Iss. 3, pp. 503-509
Closed Access | Times Cited: 1
The Biological Significance of Trogocytosis
Deborah Agbakwuru, Scott A. Wetzel
Results and problems in cell differentiation (2024), pp. 87-129
Closed Access | Times Cited: 1
Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach
O. Bar, Angel Porgador, Tomer Cooks
Journal of Extracellular Biology (2024) Vol. 3, Iss. 9
Open Access | Times Cited: 1
Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia
Vaibhav Agrawal, Lindsey Murphy, Hoda Pourhassan, et al.
European Journal Of Haematology (2023) Vol. 112, Iss. 2, pp. 236-247
Open Access | Times Cited: 2
Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis
Alexandra E. Kovach, Brent L. Wood
Seminars in Diagnostic Pathology (2023) Vol. 40, Iss. 6, pp. 457-471
Closed Access | Times Cited: 2
Histiocytic sarcoma following CAR T-cell therapy: a case report
An Kang, Yan He, Yanjing Tang, et al.
International Journal of Hematology (2024) Vol. 119, Iss. 3, pp. 338-341
Closed Access
Programmable cancer treatments: Engineering biology approaches for living cures
Marc Biarnes-Carrera, Alexandra Sevko, Nicholas Glanville, et al.
Engineering Biology (2024) Vol. 8, Iss. 2-3, pp. 31-40
Open Access
Breast cancer spheroids prefer activated macrophages as an accomplice: An in vitro study
Abhishek Teli, Ranjani Iyer, Karthik Shanbhag, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
[The mechanisms and salvage treatment strategies underlying positive relapse following CD19 CAR-T cell therapy in B-acute lymphoblastic leukemia].
Chen Lu, Jinchao Xu, Heng Mei
PubMed (2024) Vol. 45, Iss. 10, pp. 970-976
Closed Access
A Switch Protein Adapter for Anti‐LILRB4 CAR‐T Cells
Ryan Huang, Heyu Chen, Jingjing Xie, et al.
European Journal of Immunology (2024)
Closed Access
CAR T in Childhood Acute Lymphoblastic Leukemia
Friso Calkoen, Jochen Buechner
Pediatric oncology (2024), pp. 199-218
Closed Access
Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics
Hongzhe Li, Yuwen Wang, Rongrong Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Targeting Tumors
Safiya Mehraj, Shazia Ali
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 93-122
Closed Access
Page 1

Scroll to top